New Data Filtering Tool Helps Identify Pathogenic Mutations
By LabMedica International staff writers Posted on 24 Jan 2016 |
A new tool designed to assist geneticists to differentiate between pathogenic and harmless mutations is now available on the Internet.
The fraction of the genes that codes for proteins is called the exome, and genome wide analysis has revealed that while the DNA of a patient with a monogenic disease contains about 20,000 variations, only one or two are disease causing. Thus, it is that 58% of rare variants in the protein-coding exome of the general population are located in only 2% of the genes.
To help differentiate between the many harmless variations and the few that are linked to disease, investigators at the Rockefeller Institute (New York, NY, USA) developed the gene damage index (GDI). The GDI is a data analysis tool that weighs how frequently the gene is mutated in the general population and calculates the importance of a given gene in a specific disease group, including Mendelian disorders, cancer, autism, and primary immunodeficiencies.
The investigators compared GDI with the leading gene-level approaches, genic intolerance, and de novo excess, and demonstrated that GDI performed best for the detection of false positives (i.e., removing exome variants in genes irrelevant to disease), whereas genic intolerance and de novo excess performed better for the detection of true positives (i.e., assessing de novo mutations in genes likely to be disease causing).
“To find a needle in the haystack, it helps to get rid of some of the hay,” said first author Dr. Yuval Itan, a researcher in the St. Giles Laboratory of Human Genetics of Infectious Disease at the Rockefeller Institute. “Filtering out the noise, the genes that pollute the data, is crucial. With this method, up to 60% of the irrelevant variants can be removed. The Gene Damage Index will help scientists more easily sort through the large amounts of data produced by next-generation sequencing.”
The GDI study was published in the November 3, 2015, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Rockefeller Institute
The fraction of the genes that codes for proteins is called the exome, and genome wide analysis has revealed that while the DNA of a patient with a monogenic disease contains about 20,000 variations, only one or two are disease causing. Thus, it is that 58% of rare variants in the protein-coding exome of the general population are located in only 2% of the genes.
To help differentiate between the many harmless variations and the few that are linked to disease, investigators at the Rockefeller Institute (New York, NY, USA) developed the gene damage index (GDI). The GDI is a data analysis tool that weighs how frequently the gene is mutated in the general population and calculates the importance of a given gene in a specific disease group, including Mendelian disorders, cancer, autism, and primary immunodeficiencies.
The investigators compared GDI with the leading gene-level approaches, genic intolerance, and de novo excess, and demonstrated that GDI performed best for the detection of false positives (i.e., removing exome variants in genes irrelevant to disease), whereas genic intolerance and de novo excess performed better for the detection of true positives (i.e., assessing de novo mutations in genes likely to be disease causing).
“To find a needle in the haystack, it helps to get rid of some of the hay,” said first author Dr. Yuval Itan, a researcher in the St. Giles Laboratory of Human Genetics of Infectious Disease at the Rockefeller Institute. “Filtering out the noise, the genes that pollute the data, is crucial. With this method, up to 60% of the irrelevant variants can be removed. The Gene Damage Index will help scientists more easily sort through the large amounts of data produced by next-generation sequencing.”
The GDI study was published in the November 3, 2015, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Rockefeller Institute
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer